Omeros (OMER) Set to Post Earnings on Thursday

Omeros (NASDAQ:OMER) is anticipated to issue its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $37.28 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 16, 2026 at 4:30 PM ET.

Omeros (NASDAQ:OMER) last posted its earnings results on Wednesday, August 12th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analysts’ expectations of $12.69 million. On average, analysts expect Omeros to post ($0.37) EPS for the current fiscal year and $1.21 EPS for the next fiscal year.

Omeros Trading Down 1.4%

Shares of OMER stock opened at $17.30 on Wednesday. The stock has a market capitalization of $1.25 billion, a P/E ratio of 6.43 and a beta of 2.96. The firm’s 50 day moving average is $18.33 and its 200 day moving average is $13.65. Omeros has a 12 month low of $6.24 and a 12 month high of $21.24.

Insider Activity

In other news, Director Thomas J. Cable sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $18.45, for a total value of $276,750.00. Following the completion of the transaction, the director directly owned 35,067 shares in the company, valued at approximately $646,986.15. This trade represents a 29.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO David J. Borges sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $20.95, for a total transaction of $209,500.00. Following the transaction, the chief accounting officer directly owned 5,000 shares of the company’s stock, valued at approximately $104,750. This represents a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 105,906 shares of company stock valued at $1,989,705. Corporate insiders own 10.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Weiss Ratings upgraded Omeros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $22.00 price target on shares of Omeros in a report on Wednesday, October 14th. Finally, Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.33.

About Omeros

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.